Developing siRNA Therapies: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developing siRNA Therapies: A Technical Forum
Pharmaceutical Technology talked to experts in siRNA-drug development to gain insight into the characteristics, processes, and challenges of this class of therapeutics.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 39-41

Liposomal delivery

PharmTech: When the liposomally packaged siRNA drug enters the cell, how is it activated at the appropriate time to perform the appropriate function? What features of the liposome enable the drug to travel to the appropriate place in the body?

Tracy (Alnylam): Once LNPs cross into the cell, they are at first contained within an endosomal vesicle. The cationic or ionizeable lipid component of the LNP is designed to promote disruption of the endosomal membrane to promote release of the siRNA into the cytoplasm of the cell. Once the siRNA is in the cytoplasm, it is able to associate with the cellular RNAi machinery to enable RNA interference for the desired target.

Houston (MDRNA): DiLA2-based liposomes are designed to carefully balance several properties to enable successful delivery of the siRNA in the cytoplasm. Key properties include: the ability to interact with a cell to initiate internalization, or endosomal uptake; fusion with the endosome to enable endosomal escape; and release of the siRNA in the cytoplasm. These features can be designed into a specific delivery component(s), or they can be engineered into the liposome structure. Interaction with a cell surface leading to endosomal internalization is characteristically driven by nonspecific properties and is primarily manifested by a slight cationic charge on the liposome surface. Endosomal release is typically achieved by fusion of the liposome with the endosomal membrane, and requires pH-responsive characteristics. The interaction of the liposome and the endosomal membrane, in response to the pH gradient in the endosome, is usually based on the pKa of the liposome components and can be designed into the DiLA2 molecule. Ultimate release within the cytoplasm is also achieved by charge properties, again the pKa, that allows for neutrality and loss of the electrostatic attraction between a positively charged component and the negatively charged siRNA.

On the horizon

PharmTech: Looking forward, do you foresee having the ability to target various tissues and areas of the body?

Tracy (Alnylam): Yes. We and others have made significant progress over the last few years in developing delivery systems for siRNA and in understanding mechanisms of siRNA delivery. The progress made in the field in a short time has given us great optimism that we will continue to significantly broaden the target cells and tissues addressable by RNAi delivery technology.

Houston (MDRNA): The ability to target organs besides the liver via systemic delivery is a central goal for MDRNA. Given the nature of the liver to filter out particles from the systemic circulation, it will be a matter of biasing delivery away from the liver and into other organs. Physical/chemical characteristics such as size and apparent charge, and careful choice of targeting ligand may allow for this biasing and effective distribution to other tissue.

For our bladder program, dosing occurs via direct instillation into the bladder; this is more of a topical delivery approach with the intent to localize and maintain the siRNA within the bladder tissue. The goal for local delivery to other sites such as lung or skin, would focus on maximal uptake at the site of administration, and the formulation would need to be tailored to provide the characteristics most appropriate for the target cell type.

Thompson (Quark): Our near-term, newer programs focus on opportunities where we can obtain effective delivery of the siRNAs without complex formulations. We are concentrating on disease indications such as the lung, eye, and kidney where we can get effective delivery and activity of these molecules without any sort of complicated formulation. We are, however, looking at formulations, and we will consider those further downstream, but at the moment it is more cost-effective (i.e., from a cost-of-goods perspective) to use nonformulated forms of the drug. Looking forward, we at Quark are working on noninvasive routes of administration (e.g., inhalation or topical) so that patients can self-administer the drug without involving injection.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here